Gene dose results for each marker were also correlated as function of the phenotype by means of the Wilcoxon signed rank test.
Finally, a Spearman analysis was used to find any correlation of the gene dose with the age of the patients.
Graphic 1 shows the gene dose values of genes EGFR, PIK3CA, and C-myc related to the dose of HHB.
Graphic 2 presents the gene dose results for ADs and SQs separately.
Genotypes traditionally Measured associated with Representative functional Semiquantitative EM (a) phenotype genotype gene dose gene dose Active/Active *1/*1 Reference 2.0 point Active/Intermediate *1/*41 1.43 1.5 Active/Inactive *1/*4 1.02 1.0 Intermediate/Inactive *41/*4 0.73 0.5 (a) EM, extensive metabolizer.
This concept of semiquantitative gene dosing was validated by demonstrating that semiquantitative gene doses of 0.5, 1.0, and 1.5 corresponded to significantly different plasma drug concentrations at steady state under standardized dosing conditions.
The combined influence of CYP2C19 gene dose and CYP2D6 SGD is shown in Table 4.
Two studies have quantitatively examined the correlation between CYP2D6 gene dose (number of functional genes) and NT concentrations (35, 36).
Instead of counting the number of "functional" alleles and designating that number as the gene dose, we used the ASCOC values to calculate a quantitative FGD corresponding to the expected mean effect of an allele combination on the concentration of NT.
For the 10 nonpathological samples tested with a single-point estimate, the mean gene dose and SD was 0.85 [+ or -] 0.10.
Duplications or deletions of a chromosome or chromosome region containing the reference gene will distort the true HER2/neu gene dose.
This may explain the lower gene dose for the T-47D cell line than is reported in the literature.